|
1
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bridgewater J, Galle PR, Khan SA, Llovet
JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J
Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle JW, Lamarca A, Goyal L, Barriuso J
and Zhu AX: New horizons for precision medicine in biliary tract
cancers. Cancer Discov. 7:943–962. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ
and McGuire DK: Metformin in patients with type 2 diabetes and
kidney disease: A systematic review. Jama. 312:2668–2675. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schneider MB, Matsuzaki H, Haorah J,
Ulrich A, Standop J, Ding XZ, Adrian TE and Pour PM: Prevention of
pancreatic cancer induction in hamsters by metformin.
Gastroenterology. 120:1263–1270. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Camacho L, Dasgupta A and Jiralerspong S:
Metformin in breast cancer-an evolving mystery. Breast Cancer Res.
17:882015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ezewuiro O, Grushko TA, Kocherginsky M,
Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF and
Romero IL: Association of Metformin Use with outcomes in advanced
endometrial cancer treated with chemotherapy. PLoS One.
11:e01471452016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Griss T, Vincent EE, Egnatchik R, Chen J,
Ma EH, Faubert B, Viollet B, DeBerardinis RJ and Jones RG:
Metformin antagonizes cancer cell proliferation by suppressing
mitochondrial-dependent biosynthesis. PLoS Biol. 13:e10023092015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo
J, Wei X, Song P, Zhou L, Xu X and Zheng S: Metformin potentiates
the effect of arsenic trioxide suppressing intrahepatic
cholangiocarcinoma: Roles of p38 MAPK, ERK3, and mTORC1. J Hematol
Oncol. 10:592017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Green DR, Galluzzi L and Kroemer G: Cell
biology. Metabolic control of cell death. Science. 345:12502562014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Romero IL, Litchfield LM, Lengyel E
and Locasale JW: Metformin targets central carbon metabolism and
reveals mitochondrial requirements in human cancers. Cell Metab.
24:728–739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhijun H, Shusheng W, Han M, Jianping L,
Li-sen Q and Dechun L: Pre-clinical characterization of 4SC-202, a
novel class I HDAC inhibitor, against colorectal cancer cells.
Tumor Biol. 37:10257–10267. 2016. View Article : Google Scholar
|
|
16
|
Minami J, Suzuki R, Mazitschek R, Gorgun
G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, et al:
Histone deacetylase 3 as a novel therapeutic target in multiple
myeloma. Leukemia. 28:680–689. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lakshmaiah KC, Jacob LA, Aparna S,
Lokanatha D and Saldanha SC: Epigenetic therapy of cancer with
histone deacetylase inhibitors. J Cancer Res Ther. 10:469–478.
2014.PubMed/NCBI
|
|
18
|
Harting K and Knöll B: SIRT2-mediated
protein deacetylation: An emerging key regulator in brain
physiology and pathology. Eur J Cell Biol. 89:262–269. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang LT, Liou JP, Li YH, Liu YM, Pan SL
and Teng CM: A novel class I HDAC inhibitor, MPT0G030, induces cell
apoptosis and differentiation in human colorectal cancer cells via
HDAC1/PKCδ and E-cadherin. Oncotarget. 5:5651–5662. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin Y, Zhang M, Dorfman RG, Li Y, Zhao Z,
Pan Y, Zhou Q, Huang S, Zhao S, Yao Y and Zou X: Histone
deacetylase 3 overexpression in human cholangiocarcinoma and
promotion of cell growth via apoptosis inhibition. Cell Death Dis.
8:e28562017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang QL, Wang L, Zhang YW, Jiang XX, Yang
F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ and Zhao WL: The
proteasome inhibitor bortezomib interacts synergistically with the
histone deacetylase inhibitor suberoylanilide hydroxamic acid to
induce T-leukemia/lymphoma cells apoptosis. Leukemia. 23:1507–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Richon VM, Emiliani S, Verdin E, Webb Y,
Breslow R, Rifkind RA and Marks PA: A class of hybrid polar
inducers of transformed cell differentiation inhibits histone
deacetylases. Proc Natl Acad Sci USA. 95:pp. 3003–3007. 1998;
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu
W, Yu W, Dai M, Li Z, Yi C, et al: Ku80 cooperates with CBP to
promote COX-2 expression and tumor growth. Oncotarget. 6:8046–8061.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shibata T and Aburatani H: Exploration of
liver cancer genomes. Nat Rev Gastroenterol Hepatol. 11:340–349.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Tozzi F, Chen J, Fan F, Xia L,
Wang J, Gao G, Zhang A, Xia X, Brasher H, et al: Intracellular ATP
levels are a pivotal determinant of chemoresistance in colon cancer
cells. Cancer Res. 72:304–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vander Heiden MG: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shukla SK, Purohit V, Mehla K, Gunda V,
Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, et
al: MUC1 and HIF-1alpha signaling crosstalk induces anabolic
glucose metabolism to impart gemcitabine resistance to pancreatic
cancer. Cancer Cell. 32:71–87.e7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Herranz D, Ambesi-Impiombato A, Sudderth
J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA,
Castillo M, Haydu JE, et al: Metabolic reprogramming induces
resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic
leukemia. Nat Med. 21:1182–1189. 2015. View Article : Google Scholar : PubMed/NCBI
|
